Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
significant time » significant threat (Expand Search), significant gap (Expand Search)
time decrease » time increased (Expand Search), sizes decrease (Expand Search), teer decrease (Expand Search)
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
significant time » significant threat (Expand Search), significant gap (Expand Search)
time decrease » time increased (Expand Search), sizes decrease (Expand Search), teer decrease (Expand Search)
-
3421
-
3422
-
3423
-
3424
Combination therapy exhibited apoptosis in Ba/F3 EML4-ALKmutant cell models.
Published 2025Subjects: -
3425
The characteristics of patient groups were used to prove the method’s applicability.
Published 2025Subjects: -
3426
-
3427
-
3428
ROS, K<sup>+</sup> efflux and cathepsin B are required for NLRP3 activation.
Published 2025Subjects: -
3429
-
3430
-
3431
-
3432
Differences in health-related quality of life indexes after disease onset between groups.
Published 2025Subjects: -
3433
Changes in subcutaneous fat thickness and muscle mass (Approximately here).
Published 2025Subjects: -
3434
-
3435
-
3436
Ba/F3 EML4-ALK<sup>mutants</sup> exhibit variable dose-response to ABT-199 treatment.
Published 2025Subjects: -
3437
-
3438
-
3439
-
3440